Aptose Biosciences (TSE:APS) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Aptose Biosciences has initiated a pilot clinical study of its new Tuspetinib (TUS) triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients, aiming to improve response rates and survival. The therapy, which combines TUS with venetoclax and a hypomethylating agent (VEN+HMA), has shown promising results in pre-clinical models and prior trials with relapsed/refractory AML. Aptose expects to share initial data from the study before the end of the year, with clinical sites currently being activated for the trial.
For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.
